TIGERMED (03347) · Company profile · Eqvero

TIGERMED

03347HKEX

Unit: CNY	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	6.71 bn CNY	6.47 bn CNY	7.29 bn CNY	7.09 bn CNY	5.19 bn CNY
Cost of revenue	4.63 bn CNY	4.03 bn CNY	4.23 bn CNY	4.3 bn CNY	2.75 bn CNY
Research and development expense	257.64 m CNY	238.39 m CNY	261.56 m CNY	234.62 m CNY	211.83 m CNY
Selling, general and administrative expense	960.57 m CNY	944.45 m CNY	837.52 m CNY	793.21 m CNY	676.88 m CNY
Operating profit after depreciation	608.47 m CNY	1.01 bn CNY	1.69 bn CNY	1.73 bn CNY	1.34 bn CNY
Operating profit before depreciation	935.21 m CNY	1.33 bn CNY	2 bn CNY	1.73 bn CNY	1.53 bn CNY
EBIT	608.47 m CNY	1.01 bn CNY	1.69 bn CNY	1.73 bn CNY	1.34 bn CNY
EBITDA	935.21 m CNY	1.33 bn CNY	2 bn CNY	1.73 bn CNY	1.53 bn CNY
Interest expense	90.56 m CNY	141.24 m CNY	119.9 m CNY	83.18 m CNY	24.91 m CNY
Profit before tax	1 bn CNY	664.46 m CNY	2.49 bn CNY	2.59 bn CNY	3.68 bn CNY
Income tax expense	198.16 m CNY	216.63 m CNY	338.61 m CNY	313.65 m CNY	292.86 m CNY
Income before extraordinary items	887.89 m CNY	405.14 m CNY	2.02 bn CNY	2.02 bn CNY	2.87 bn CNY
Common dividends	107.75 m CNY	256.54 m CNY	491.29 m CNY	475.72 m CNY	433.19 m CNY
Total dividends	107.75 m CNY	256.54 m CNY	491.29 m CNY	475.72 m CNY	433.19 m CNY

Quotes are end-of-day data. Content is for research purposes and is not investment advice.